Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOI, etc.
Berberine (BBR) is an active component in traditional Chinese medicine with a long history of clinical application. In recent years, its remarkable multi-target pharmacological properties have attracted extensive attention in modern biomedical research. Traditionally known for its antibacterial and anti-inflammatory effects, BBR is now widely used in the treatment of metabolic disorders, cardiovascular diseases, cancer, and neurological diseases. However, due to its low oral bioavailability, clinical translation has been severely limited. Moreover, BBR mainly accumulates in the intestine, resulting in a low systemic exposure level, which leads to a gap between the effective concentration in the preclinical stage and the actual achievable plasma concentration level. This article focuses on the bottleneck issue of BBR’s bioavailability, providing a comprehensive and systematic summary from aspects such as multi-target action mechanisms, synergistic combination strategies, carrier-free self-assembling formulation methods, as well as existing research evidence, drug transformation prospects, safety issues, and drug interactions. It clarifies the existing opportunities and challenges of BBR, aiming to promote the further development of BBR therapy and provide new ideas for its clinical translation.
Comments on this article